Kentucky Attorney General Jack Conway announced the settlement of two dangerous drug lawsuits for a total of $39.5 million.
The settlements end the litigation of the Purdue Pharma case regarding OxyContin and the Johnson & Johnson case regarding its antipsychotic drug Risperdal.
The OxyContin case was settled on Dec. 22 for $24 million – more than 50 times what Kentucky was originally offered in 2007 to settle the case.
The Risperdal lawsuit alleging that Johnson & Johnson falsely marketed the drug and hid serious Risperdal side effects from patients and the medical community was settled the same day for $15.5 million.
“These companies engaged in reckless behavior that put our citizens at risk,” Attorney General Conway said. “Both companies knowingly and aggressively marketed drugs they knew to be harmful in order to drive profits. I am pleased we were able to recover damages for the Commonwealth and recover funds to help expand addiction treatment in Kentucky.”
Risperdal Settlement
Risperdal is an antipsychotic prescription drug approved by the FDA to treat schizophrenia and acute mania associated with bipolar disorder as well as certain autism spectrum disorders. The drug is manufactured and distributed by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson.
The Kentucky Risperdal lawsuit alleged that the makers of Risperdal misled consumers about its dangers and marketed the drug for purposes other than those approved by the FDA.
“Janssen and Johnson & Johnson put patients at risk when they marketed Risperdal without disclosing the drug’s known side effects,” Attorney General Conway said. “These side effects were even more harmful to children and elderly patients.”
Janssen allegedly marketed Risperdal to children before it was approved to do so in 2007 by the FDA, failing to disclose to the medical community that Risperdal may cause a hormonal imbalance, which could lead to the development of male breast growth or gynecomastia. Janssen was allegedly aware of the Risperdal gynecomastia risk and did not update the drug’s warning label.
Janssen also marketed Risperdal for non-FDA approved use in treating dementia in non-schizophrenic elderly patients. In 2013, Janssen pleaded guilty to federal charges of misbranding the drug regarding its promotions to the elderly.
In addition to the $15.5 million payment to settle the Risperdal lawsuit, Janssen is prohibited from promoting Risperdal for non-FDA approved uses or to populations in which it is not approved. Janssen will now be required in Kentucky to clearly disclose risks associated with the drug.
The company will also not be allowed to promote the drug for a single symptom for which it is not approved, such as depression or anxiety, without reference to the underlying mental illnesses that Risperdal is approved by the FDA to treat.
The settlement also resolves allegations that Purdue Pharma illegally misrepresented and/or concealed the highly addictive nature of OxyContin and encouraged doctors who weren’t trained in pain management to overprescribe the opioid pain reliever to Kentucky patients.
In the settlements, neither company admits any wrongdoing.
The OxyContin lawsuit is Kentucky v. Purdue Pharma LP et al., Case No. 07-CI-01303, in the Pike Circuit Court of the Commonwealth of Kentucky. The Risperdal lawsuit is Kentucky v. Janssen Pharmaceuticals Inc. et al., Case No. 13-CI-002488, in the Jefferson Circuit Court of the Commonwealth of Kentucky.
Do YOU have a legal claim? Fill out the form on this page now for a free, immediate, and confidential case evaluation. The Risperdal attorneys who work with Top Class Actions will contact you if you qualify to let you know if an individual lawsuit or Risperdal class action lawsuit is best for you. [In general, Risperdal lawsuits are filed individually by each plaintiff and are not class actions.] Hurry — statutes of limitations may apply.
Top Class Actions is a Proud Member of the American Bar Association
LEGAL INFORMATION IS NOT LEGAL ADVICE
Top Class Actions Legal Statement
©2008 – 2016 Top Class Actions® LLC
Various Trademarks held by their respective owners
Get Help – It’s Free
Join a Free Risperdal Class Action Lawsuit Investigation
If you or your son took Risperdal between the ages of 10 and 18 years old and suffered gynecomastia (male breast growth), male breast pain, nipple pain, or nipple discharge, you may be entitled to compensation. See if you qualify by submitting your information below for a free and confidential case review.
An attorney will contact you if you qualify to discuss the details of your potential case at no charge to you.
- First Name*
- Last Name*
- Street Address*
- Apt. #
- City*
- State*
AlabamaAlaskaArizonaArkansasCaliforniaColoradoConnecticutDelawareDistrict of ColumbiaFloridaGeorgiaHawaiiIdahoIllinoisIndianaIowaKansasKentuckyLouisianaMaineMarylandMassachusettsMichiganMinnesotaMississippiMissouriMontanaNebraskaNevadaNew HampshireNew JerseyNew MexicoNew YorkNorth CarolinaNorth DakotaOhioOklahomaOregonPennsylvaniaRhode IslandSouth CarolinaSouth DakotaTennesseeTexasUtahVermontVirginiaWashingtonWest VirginiaWisconsinWyomingArmed Forces AmericasArmed Forces EuropeArmed Forces Pacific
- Zip Code*
- Phone*
- Email*
- If you're filling this out for a loved one, what is the name of the person who took Risperdal?*
- Are you/your loved one a male who took Risperdal between the ages of 10 and 18 years old?*
YesNo
- What year was the person who took Risperdal born?*
- How old was this person when they took Risperdal?*
- Please check the Risperdal injuries suffered:*
-
Breast Growth
-
Breast Pain
-
Nipple Pain
-
Nipple Discharge
-
- How old were you/your loved one when these problems began?*
- ¿Necesita un orador español?
- Yes
- No
- Please enter any additional details you would like the staff reviewing your submission to know.
- I understand and agree that submitting this form does not create an attorney-client relationship and that the information I submit is not confidential or privileged and may be shared.*
-
Yes
-
-
if(typeof gf_global == ‘undefined’) var gf_global = {“gf_currency_config”:{“name”:”U.S. Dollar”,”symbol_left”:”$”,”symbol_right”:””,”symbol_padding”:””,”thousand_separator”:”,”,”decimal_separator”:”.”,”decimals”:2},”base_url”:”http:\/\/topclassactions.com\/wp-content\/plugins\/gravityforms”,”number_formats”:[],”spinnerUrl”:”http:\/\/topclassactions.com\/wp-content\/plugins\/gravityforms\/images\/spinner.gif”};jQuery(document).bind(‘gform_post_render’, function(event, formId, currentPage){if(formId == 25) {gformInitChosenFields(‘#input_25_5′,’No results matched’);if(!/(android)/i.test(navigator.userAgent)){jQuery(‘#input_25_7’).mask(‘(999) 999-9999’).bind(‘keypress’, function(e){if(e.which == 13){jQuery(this).blur();} } );}} } );jQuery(document).bind(‘gform_post_conditional_logic’, function(event, formId, fields, isInit){gformInitChosenFields(‘#input_25_5′,’No results matched’);} ); jQuery(document).ready(function(){jQuery(document).trigger(‘gform_post_render’, [25, 1]) } );
The post Kentucky AG Announces $39.5M Settlement in Risperdal, Oxycontin Lawsuits appeared first on Top Class Actions.
No comments:
Post a Comment